| Identification | Back Directory | [Name]
SCH 42495 | [CAS]
136511-43-8 | [Synonyms]
SCH 42495
ETHYL N-{2-[(ACETYLTHIO)METHYL]-3-(O-TOLYL)-1-OXOPROPYL}-L-METHIONATE
N-(2(S)-(Acetylthiomethyl)-3-(2-Methylphenyl)-1- Oxopropyl)-L-Methionine Ethyl Ester
L-Methionine, N-[(2S)-2-[(acetylthio)methyl]-3-(2-methylphenyl)-1-oxopropyl]-, ethyl ester | [Molecular Formula]
C20H29NO4S2 | [MOL File]
136511-43-8.mol | [Molecular Weight]
411.58 |
| Hazard Information | Back Directory | [Uses]
SCH 42495 is an orally active neutral metalloendopeptidase (NEP) inhibitor with antihypertensive effect. SCH 42495 is the orally active ethylester proagent of SCH 42354[1]. | [in vivo]
SCH 42495 (30 mg/kg; oral gavage; twice daily) causes a significant reduction in the pulmonary vascular remodelling and ventricular hypertrophy in hypoxic rats after 10 days[2].
Treatment with SCH 42495 (30 mg/kg; oral gavage; twice daily) leads to a decrease in cardiovascular remodelling secondary to chronic hypoxia in rats[2].
SCH 42495 (oral doses of 1, 3, or 10 mg/kg) produces significant reductions in blood pressure in DOCA-N a hypertensive rats of 22±6, 43±7, and 62±12 mm Hg, respectively[1]. | Animal Model: | Hypoxic rats[2] | | Dosage: | 30 mg/kg | | Administration: | Oral gavage; twice daily for 10 days | | Result: | Caused a significant reduction in the pulmonary vascular remodelling and ventricular hypertrophy.
Led to a decrease in cardiovascular remodelling secondary to chronic hypoxia. |
| [References]
[1] Watkins RW, et al. Atrial natriuretic factor potentiating and hemodynamic effects of SCH 42495, a new, neutral metalloendopeptidase inhibitor. Am J Hypertens. 1993 May;6(5 Pt 1):357-68. DOI:10.1093/ajh/6.5.357
[2] Thompson JS, et al. Effects of the neutral endopeptidase inhibitor, SCH 42495, on the cardiovascular remodelling secondary to chronic hypoxia in rats. Clin Sci (Lond). 1994 Jul;87(1):109-14. DOI:10.1042/cs0870109 |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|